RxDoctor Payments Data

Christina Frankenfield, NP

Nurse Practitioner · Uniontown, PANPI 1265823850

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 67 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$466
  • Novo Nordisk$234
  • Pfizer$212
  • Otsuka America Pharmaceutical, Inc.$195
  • AbbVie$165
  • GSK$85
  • plus $457 from 15 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,331
Medicare patients
51
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$65,682
TrulicityDulaglutide49$51,933
Atorvastatin Calcium511$49,043
TradjentaLinagliptin87$42,577
Aripiprazole49$30,958
JardianceEmpagliflozin51$28,889
Pantoprazole Sodium142$28,361
OzempicSemaglutide25$26,750
Omeprazole255$26,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$24,794
Gabapentin393$24,434
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate79$18,831
ClopidogrelClopidogrel Bisulfate152$18,359
Tamsulosin Hcl171$15,163
Duloxetine Hcl96$14,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance$17$71,467138 claims
PfizerEliquis$212$65,682127 claims
Lilly USA, LLCTrulicity$15$51,93349 claims
GSKTrelegy Ellipta, Incruse Ellipta$85$38,65173 claims
Novo NordiskOzempic$234$26,75025 claims
AstraZenecaBrilinta$466$5,33512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Uniontown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →